Factors Associated with First-Line Antiretroviral Therapy Failure amongst HIV-Infected African Patients: A Case-Control Study


Background: Since 2001, anti-retroviral therapy (ART) has been provided to over 75,000 HIV-infected patients at the USAID-Academic Model Providing Access to Healthcare (AMPATH) Partnership in western Kenya. Over 1000 of these patients have switched to second-line ART. We therefore set out to determine factors associated with first-line ART failure amongst these patients. Methods: This case controlled study matched patients (in the ratio 1:2) from the electronic AMPATH Medical Record System on the basis of age, gender, and ART initiation date. Cases were adults (≥18 years) who initiated second-line ART between January 1, 2007 and July 31, 2011 after at least one viral load measurement >5000 copies/ml or satisfying the WHO immunological or clinical failure criteria. Controls were those on non-failing first-line ART with a CD4 count > 400 /ml within the last 12 months, at the time of case incidence. Conditional logistic regression for paired data was used to assess association. We evaluated the strength of association of risk factors using stratified Cox model. Results: Of the 1084 cases and 2149 controls included in the analysis, 62% were female. Median age was 36.5 years (IQR = 30.7 - 43.1); median baseline CD4 cell count was 161 /ml (IQR = 72 - 277); Median time to ART failure was 37 months (IQR = 24 - 47). Low baseline CD4 count < 50 /ml (H.R = 7.07, (95% CI = 4.92 - 10.15); Zidovudine based ART (H.R 1.76, 95% CI = 1.25 - 2.48) and imperfect ART adherence (H.R = 2.77, 95% CI = 2.20 - 3.49) were independently associated with treatment failure. Conclusion: In this setting, low baseline CD4 count, zidovudine-based ART and imperfect adherence are associated with first-line ART treatment failure.

Share and Cite:

C. M. Kwobah, A. W. Mwangi, J. K. Koech, G. N. Simiyu and A. M. Siika, "Factors Associated with First-Line Antiretroviral Therapy Failure amongst HIV-Infected African Patients: A Case-Control Study," World Journal of AIDS, Vol. 2 No. 4, 2012, pp. 271-278. doi: 10.4236/wja.2012.24036.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] P. Lewthwaite and E. Wilkins, “Natural History of HIV/AIDS,” Medicine, Vol. 37, No. 7, 2009, pp. 333-337. doi:10.1016/j.mpmed.2009.04.015
[2] A. Mindel and M. Tenant-Flowers, “Natural History and Management of Early HIV Infection,” BMJ, Vol. 322, No. 7297, 2001, pp. 1290-1293. doi:10.1136/bmj.322.7297.1290
[3] A. Siika, P. Ayuo, J. Sidle, A. Mwangi, K. Wools-Kaloustian, S. Kimaiyo, et al., “Admission Characteristics, Diagnoses and Outcomes of HIV-Infected Patients Registered in an Ambulatory HIV-Care Programme in Western Kenya,” East African Medical Journal, Vol. 85, No. 11, 2008, pp. 523-528.
[4] R. S. Hogg, B. Yip, C. Kully, K. Craib, M. O’Shaughnessy, M. Schechter, et al., “Improved Survival among HIV-Infected Patients after Initiation of Triple-Drug Antiretroviral Regimens,” Canadian Medical Association Journal, Vol. 160, No. 5, 1999, pp. 659-665.
[5] M. Egger, B. Hirschel, P. Francioli, P. Sudre, M. Wirz, M. Flepp, et al., “Impact of New Antiretroviral Combination Therapies in HIV Infected Patients in Switzerland: Prospective Multicentre Study. Swiss HIV Cohort Study,” BMJ, Vol. 315, No. 7117, 1997, pp. 1194-1199. doi:10.1136/bmj.315.7117.1194
[6] O. Keiser, H. Tweya, P. Braitstein, F. Dabis, P. MacPhail, A. Boulle, et al., “Mortality after Failure of Antiretroviral Therapy in Sub-Saharan Africa,” Tropical Medicine & International Health, Vol. 15, No. 2, 2010, pp. 251-258. doi:10.1111/j.1365-3156.2009.02445.x
[7] A. Mocroft, B. Ledergerber, J. P. Viard, S. Staszewski, M. Murphy, A. Chiesi, et al., “Time to Virological Failure of 3 Classes of Antiretrovirals after Initiation of Highly Active Antiretroviral Therapy: Results from the EuroSIDA Study Group,” The Journal of Infectious Diseases, Vol. 190, No. 11, 2004, pp. 1947-1956. doi:10.1086/425424
[8] D. Cadosch, S. Bonhoeffer and R. Kouyos, “Assessing the Impact of Adherence to Anti-Retroviral Therapy on Treatment Failure and Resistance Evolution in HIV,” Journal of the Royal Society, Interface/the Royal Society, Vol. 9, No. 74, 2012, pp. 2309-2320.
[9] M. I. Datay, A. Boulle, D. Mant and P. Yudkin, “Associations with Virologic Treatment Failure in Adults on Antiretroviral Therapy in South Africa,” Journal of Acquired Immune Deficiency Syndromes, Vol. 54, No. 5, 2010, pp. 489-495. doi:10.1097/QAI.0b013e3181d91788
[10] Y. Ma, D. Zhao, L. Yu, M. Bulterys, M. L. Robinson, Y. Zhao, et al., “Predictors of Virologic Failure in HIV-1-Infected Adults Receiving First-Line Antiretroviral Therapy in 8 Provinces in China,” Clinical Infectious Diseases, Vol. 50, No. 2, 2010, pp. 264-271. doi:10.1086/649215
[11] P. R. Harrigan, R. S. Hogg, W. W. Y. Dong, B. Yip, B. Wynhoven, J. Woodward, et al., “Predictors of HIV Drug-Resistance Mutations in a Large Antiretroviral-Naive Cohort Initiating Triple Antiretroviral Therapy,” Journal of Infectious Diseases, Vol. 193, No. 3, 2005, pp. 339-347. doi:10.1086/427192
[12] Kenya Aids Indicator Survey, 2007. http://www.nacc.or.ke/nacc%20downloads/ official_kais_report_2009.pdf.
[13] W. M. Tierney, J. K. Rotich, T. J. Hannan, A. Siika, P. G. Biondich, B. W. Mamlin, et al., “The AMPATH Medical Record System: Creating, Implementing, and Sustaining an Electronic Medical Record System to Support HIV/AIDS Care in Western Kenya,” Study in Health Technology and Informatics, Vol. 129, 2007, pp. 372-376.
[14] SAS Macros, 2012. http://mayoresearch.mayo.edu/mayo/ research/biostat/sasmacros.cfm
[15] World Health Organization, “Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach—2006 Revision,” 2012. http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf
[16] B. Langholz and D. C. Thomas, “Nested Case-Control and Case-Cohort Methods of Sampling from a Cohort: A Critical Comparison,” American Journal of Epidemiology, Vol. 131, No. 1, 1990, pp. 169-176.
[17] N. Khienprasit, R. Chaiwarith, T. Sirisanthana and K. Supparatpinyo, “Incidence and Risk Factors of Antiretroviral Treatment Failure in Treatment-Naive HIV-Infected Patients at Chiang Mai University Hospital, Thailand,” AIDS Research and Therapy, Vol. 8, No. 1, 2011, p. 42. doi:10.1186/1742-6405-8-42
[18] A. Soria, K. Porten, J.-C. Fampou-Toundji, L. Galli, R. Mougnutou, V. Buard, et al., “Resistance Profiles after Different Periods of Exposure to a First-Line Antiretroviral Regimen in a Cameroonian Cohort of HIV Type-1-Infected Patients,” Antiviral Therapy (Lond.), Vol. 14, No. 3, 2009, pp. 339-347.
[19] J.-F. Faucher, B. Challier, C. Chirouze, C. Drobacheff, P. Fischer, J.-M. Lang, et al., “Predictive Factors of Virological Response to Primary Antiretroviral Treatment,” La Presse Médicale, Vol. 33, No. 5, 2004, pp. 310-315. doi:10.1016/S0755-4982(04)98570-3
[20] D. T. M. Huong, W. Bannister, P. T. Phong, O. Kirk and L. Peters, “Factors Associated with HIV-1 Virological Failure in an Outpatient Clinic for HIV-Infected People in Haiphong, Vietnam,” International Journal of STD & AIDS, Vol. 22, No. 11, 2011, pp. 659-664. doi:10.1258/ijsa.2011.010515
[21] G. I. Eluwa, T. Badru and K. J. Akpoigbe, “Adverse Drug Reactions to Antiretroviral Therapy (ARVs): Incidence, Type and Risk Factors in Nigeria,” BMC Clinical Pharmacology, Vol. 12, 2012, p. 7. doi:10.1186/1472-6904-12-7
[22] E. DeJesus, G. Herrera, E. Teofilo, J. Gerstoft, C. B. Buendia, J. D. Brand, et al., “Abacavir versus Zidovudine Combined with Lamivudine and Efavirenz, for the Treatment of Antiretroviral-Naive HIV-Infected Adults,” Clinical Infectious Diseases, Vol. 39, No. 7, 2004, pp. 1038-1046. doi:10.1086/424009
[23] P. L. Anderson and J. E. Rower, “Zidovudine and Lamivudine for HIV Infection,” Clinical Medicine Reviews in Therapeutics, Vol. 2, 2010, p. a2004.
[24] K. E. Squires, R. Gulick, P. Tebas, J. Santana, V. Mulanovich, R. Clark, et al., “A Comparison of Stavudine plus Lamivudine versus Zidovudine plus Lamivudine in Combination with Indinavir in Antiretroviral Naive Individuals with HIV Infection: Selection of Thymidine Analog Regimen Therapy (START I),” AIDS, Vol. 14, No. 11, 2000, pp. 1591-1600. doi:10.1097/00002030-200007280-00015
[25] N. A. Foudraine, J. J. de Jong, G. Jan-Weverling, B. H. van Benthem, J. Maas, I. P. Keet, et al., “An Open Randomized Controlled Trial of Zidovudine plus Lamivudine versus Stavudine plus Lamivudine,” AIDS, Vol. 12, No. 12, 1998, pp. 1513-1519. doi:10.1097/00002030-199812000-00014
[26] M. W. Kline, R. B. Van Dyke, J. C. Lindsey, M. Gwynne, M. Culnane, R. E. McKinney Jr., et al., “A Randomized Comparative Trial of Stavudine (d4T) versus Zidovudine (ZDV, AZT) in Children with Human Immunodeficiency Virus Infection. AIDS Clinical Trials Group 240 Team,” Pediatrics, Vol. 101, No. 2, 1998, pp. 214-220. doi:10.1542/peds.101.2.214
[27] R. Manfredi, L. Calza and F. Chiodo, “Efavirenz versus Nevirapine in Current Clinical Practice: A Prospective, Open-Label Observational Study,” Journal of Acquired Immune Deficiency Syndromes, Vol. 35, No. 5, 2004, pp. 492-502. doi:10.1097/00126334-200404150-00007
[28] C. W. Wester, A. M. Thomas, H. Bussmann, S. Moyo, J. M. Makhema, T. Makhema, et al., “Non-Nucleoside Reverse Transcriptase Inhibitor Outcomes among Combination Antiretroviral Therapy-Treated Adults in Botswana,” AIDS, Vol. 24, Suppl. 1, 2010, pp. S27-S36. doi:10.1097/01.aids.0000366080.91192.55
[29] H. Li, W. Guo, H. Li, Z. Wang, Y.-J. Liu, Z.-Y. Bao, et al., “Occurrence of Human Immunodeficiency Virus-1 Resistance through a Six-Year Surveillance in Rural Areas of Henan,” Zhonghua Yi Xue Za Zhi, Vol. 91, No. 21, 2011, pp. 1443-1447.
[30] G. Wandeler, O. Keiser, K. Pfeiffer, S. Pestilli, C. Fritz, N. D. Labhardt, et al., “Outcomes of Antiretroviral Treatment Programs in Rural Southern Africa,” Journal of Acquired Immune Deficiency Syndromes, Vol. 59, No. 2, 2012, pp. e9-e16. doi:10.1097/QAI.0b013e31823edb6a
[31] O. Keiser, B. H. Chi, T. Gsponer, A. Boulle, C. Orrell, S. Phiri, et al., “Outcomes of Antiretroviral Treatment in Programmes with and without Routine Viral Load Monitoring in Southern Africa,” AIDS, Vol. 25, No. 14, 2011, pp. 1761-1769. doi:10.1097/QAD.0b013e328349822f
[32] F. P. Sarasin, A. Perrier and T. Rochat, “Isoniazid Preventive Therapy for Pulmonary Tuberculosis Sequelae: Which Patients up to Which Age?” Tubercle and Lung Disease, Vol. 76, No. 5, 1995, pp. 394-400. doi:10.1016/0962-8479(95)90004-7
[33] C. Kabali, C. F. von Reyn, D. R. Brooks, R. Waddell, L. Mtei, M. Bakari, et al., “Completion of Isoniazid Preventive Therapy and Survival in HIV-Infected, TST-Positive Adults in Tanzania,” International Journal of Tuberculosis and Lung Disease, Vol. 15, No. 11, 2011, pp. 1515-1521. doi:10.5588/ijtld.10.0788
[34] M. Khongphatthanayothin, A. Avihingsanon, N. Teeratakulpisarn, N. Phanuphak, R. Buajoom, P. Suwanmala, et al., “Feasibility and Efficacy of Isoniazid Prophylaxis for Latent Tuberculosis in HIV-Infected Clients Patients in Thailand,” AIDS Research and Human Retroviruses, Vol. 28, No. 3, 2012, pp. 270-275. doi:10.1089/aid.2011.0041
[35] P.-L. Lim, J. Zhou, R. A. Ditangco, M. G. Law, T. Sirisanthana, N. Kumarasamy, et al., “Failure to Prescribe Pneumocystis Prophylaxis Is Associated with Increased Mortality, even in the cART Era: Results from the Treat Asia HIV Observational Database,” Journal of the International AIDS Society, Vol. 15, No. 1, 2012, p. 1. doi:10.1186/1758-2652-15-1
[36] P. Braitstein, A. Siika, J. Hogan, R. Kosgei, E. Sang, J. Sidle, et al., “A Clinician-Nurse Model to Reduce Early Mortality and Increase Clinic Retention among High-Risk HIV-Infected Patients Initiating Combination Antiretroviral Treatment,” Journal of International AIDS Society, Vol. 15, 2012, p. 7. doi:10.1186/1758-2652-15-7

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.